Chimeric interleukin-6 soluble receptor/ligand proteins

Details Chimeric interleukin-6 soluble receptor/ligand proteins Chimeric interleukin-6 soluble receptor/ligand proteins

2007-04-03

2007-04-03

Andres, Janet (Department: 1649)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C530S350000, C530S351000, C514S012200

Reexamination Certificate

active

09462416

ABSTRACT:
Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.

REFERENCES:
patent: 6372207 (2002-04-01), Tepper et al.
patent: 0 413 908 (1991-02-01), None
patent: 0 538 810 (1993-04-01), None
patent: 0 888 384 (2002-12-01), None
patent: 96 36354 (1996-11-01), None
patent: 97 32891 (1997-09-01), None
Lust, J.A. et al. 1995, Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R). Curr Top Microbiol Immunol. 194:199-206.
Sambrook, J. et al. 1989. Molecular cloning—a laboratory manual. Cold Spring Harbor Press. pp. 9.47-9.51 and 11.38-11.49.
Yawata, H et al. 1993. Structure-function analysis of human IL-6 receptor: dissociation of amino acid resudues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO J 12(4):1705-1712.
Paonessa, G. et al. 1995. Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signalling. EMBO J 14(9):1942-1951.
Mazumder, B. et al. 2003. Translational control by the 3′ UTR: the ends specify the means. Trends in Biochemical Sciences 28:91-98.
Weich et al. 1993. Experimental Hematology 21:647-655.
Chen et al. 1997. Proc Natl Acad Sci USA 94:6910-6915.
Chebath et al., “Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleulin-6 type pleiotropic activities”,Eur. Cytokine News, vol. 8, No. 4, pp. 359-365, (1997).
Sui et al., “gp130 and c-Kit signaling synergize for ex vivo expansion of human primitives hemopoietic progenitor cells”,Proc. Natl., Acad. Sci., vol. 92, pp. 2859-2863, (1995).
Mackiewicz et al., “Interleukin-6-Type Cytokines and Their Receptors for Gene Therapy of Melanoma”, pp. 361-374, (1995).
Fischer et al., A bioactive designer cytokine for human hematopoietic progenitor cell expansion,Nature Biotechnology, vol. 15, pp. 142-144, (1997).
Kollet et al., “Soluble IL-6 receptor/IL-6 fusion protein enhance maintenance and proliferation of human CD34/CD38 stem cells in vitro”, pp. 394, (1997).
Kollet, O., et al. Blood. 90 (10 Suppl. 1 part 1), Nov. 15, 1997; 394A.
Mackiewicz, A., et al. Ann. NY Acad. Sci. Jul. 21, 1995; 762:361-73; discussion 373-4.

Affiliated with

Also associated with

Rating

Chimeric interleukin-6 soluble receptor/ligand proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric interleukin-6 soluble receptor/ligand proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric interleukin-6 soluble receptor/ligand proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3797306